Yukami H, et al. - Considering a promising therapeutic value of the combination of irinotecan, cisplatin, and S-1 (IPS) for advanced gastric cancer (AGC), researchers undertook a phase I study of IPS determining the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and recommended dose (RD) in patients with AGC. They administered an escalating dose of intravenous irinotecan (level 1: 100/level 2: 125/level 3: 150 mg/m^²) on day 1, a fixed dose of intravenous cisplatin (60 mg/m^²) on day 1, a fixed dose of S-1 (80 mg/m^² BID) orally on days 1-14, every 4 weeks, to the patients. As per outcomes, the determined RD of IPS is 100 mg/m² of irinotecan, 60 mg/m^² of cisplatin, and 80 mg/m^² of S-1. This regimen was noted to have acceptable antitumor activity and a favorable toxicity profile.